Literature DB >> 33468204

Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.

Ria Thomas1, Elizabeth B Moloney1, Zachary K Macbain1, Penelope J Hallett2, Ole Isacson3.   

Abstract

Lysosomal dysfunction is a central pathway associated with Parkinson's disease (PD) pathogenesis. Haploinsufficiency of the lysosomal hydrolase GBA (encoding glucocerebrosidase (GCase)) is one of the largest genetic risk factors for developing PD. Deficiencies in the activity of the GCase enzyme have been observed in human tissues from both genetic (harboring mutations in the GBA gene) and idiopathic forms of the disease. To understand the mechanisms behind the deficits of lysosomal GCase enzyme activity in idiopathic PD, this study utilized a large cohort of fibroblast cells from control subjects and PD patients with and without mutations in the GBA gene (N370S mutation) (control, n = 15; idiopathic PD, n = 31; PD with GBA N370S mutation, n = 6). The current data demonstrates that idiopathic PD fibroblasts devoid of any mutations in the GBA gene also exhibit reduction in lysosomal GCase activity, similar to those with the GBA N370S mutation. This reduced GCase enzyme activity in idiopathic PD cells was accompanied by decreased expression of the GBA trafficking receptor, LIMP2, and increased ER retention of the GBA protein in these cells. Importantly, in idiopathic PD fibroblasts LIMP2 protein levels correlated significantly with GCase activity, which was not the case in control subjects or in genetic PD GBA N370S cells. In conclusion, idiopathic PD fibroblasts have decreased GCase activity primarily driven by altered LIMP2-mediated transport of GBA to lysosome and the reduced GCase activity exhibited by  the genetic GBA N370S derived PD fibroblasts occurs through a different mechanism.

Entities:  

Keywords:  GBA; Idiopathic PD fibroblasts; LIMP2; Lysosomal dysfunction

Year:  2021        PMID: 33468204      PMCID: PMC7816505          DOI: 10.1186/s13041-020-00712-3

Source DB:  PubMed          Journal:  Mol Brain        ISSN: 1756-6606            Impact factor:   4.041


  68 in total

1.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 2.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

3.  Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.

Authors:  Lucilla Parnetti; Silvia Paciotti; Paolo Eusebi; Andrea Dardis; Stefania Zampieri; Davide Chiasserini; Anna Tasegian; Nicola Tambasco; Bruno Bembi; Paolo Calabresi; Tommaso Beccari
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

4.  Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.

Authors:  Katherine R Smith; John Damiano; Silvana Franceschetti; Stirling Carpenter; Laura Canafoglia; Michela Morbin; Giacomina Rossi; Davide Pareyson; Sara E Mole; John F Staropoli; Katherine B Sims; Jada Lewis; Wen-Lang Lin; Dennis W Dickson; Hans-Henrik Dahl; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2012-05-17       Impact factor: 11.025

5.  A mutation in SCARB2 is a modifier in Gaucher disease.

Authors:  Arash Velayati; John DePaolo; Nidhi Gupta; Jae H Choi; Nima Moaven; Wendy Westbroek; Ozlem Goker-Alpan; Ehud Goldin; Barbara K Stubblefield; Edwin Kolodny; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2011-09-15       Impact factor: 4.878

6.  The role of SCARB2 as susceptibility factor in Parkinson's disease.

Authors:  Franziska Hopfner; Eva C Schulte; Brit Mollenhauer; Benjamin Bereznai; Franziska Knauf; Peter Lichtner; Alexander Zimprich; Dietrich Haubenberger; Walter Pirker; Thomas Brücke; Annette Peters; Christian Gieger; Gregor Kuhlenbäumer; Claudia Trenkwalder; Juliane Winkelmann
Journal:  Mov Disord       Date:  2013-02-13       Impact factor: 10.338

Review 7.  The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.

Authors:  Marco Toffoli; Laura Smith; Anthony H V Schapira
Journal:  J Neurochem       Date:  2020-02-03       Impact factor: 5.372

8.  Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.

Authors:  Mylene Huebecker; Elizabeth B Moloney; Aarnoud C van der Spoel; David A Priestman; Ole Isacson; Penelope J Hallett; Frances M Platt
Journal:  Mol Neurodegener       Date:  2019-11-08       Impact factor: 14.195

9.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.

Authors:  Jose Bras; Rita Guerreiro; Lee Darwent; Laura Parkkinen; Olaf Ansorge; Valentina Escott-Price; Dena G Hernandez; Michael A Nalls; Lorraine N Clark; Lawrence S Honig; Karen Marder; Wiesje M Van Der Flier; Afina Lemstra; Philip Scheltens; Ekaterina Rogaeva; Peter St George-Hyslop; Elisabet Londos; Henrik Zetterberg; Sara Ortega-Cubero; Pau Pastor; Tanis J Ferman; Neill R Graff-Radford; Owen A Ross; Imelda Barber; Anne Braae; Kristelle Brown; Kevin Morgan; Walter Maetzler; Daniela Berg; Claire Troakes; Safa Al-Sarraj; Tammaryn Lashley; Yaroslau Compta; Tamas Revesz; Andrew Lees; Nigel Cairns; Glenda M Halliday; David Mann; Stuart Pickering-Brown; Dennis W Dickson; Andrew Singleton; John Hardy
Journal:  Hum Mol Genet       Date:  2014-06-27       Impact factor: 6.150

10.  SCARB2 variants and glucocerebrosidase activity in Parkinson's disease.

Authors:  Roy N Alcalay; Oren A Levy; Pavlina Wolf; Petra Oliva; Xiaokui Kate Zhang; Cheryl H Waters; Stanley Fahn; Un Kang; Christopher Liong; Blair Ford; Pietro Mazzoni; Sheng Kuo; Amelie Johnson; Lan Xiong; Guy A Rouleau; Wendy Chung; Karen S Marder; Ziv Gan-Or
Journal:  NPJ Parkinsons Dis       Date:  2016-03-10
View more
  4 in total

Review 1.  Glycosphingolipid metabolism and its role in ageing and Parkinson's disease.

Authors:  Kerri-Lee Wallom; María E Fernández-Suárez; David A Priestman; Danielle Te Vruchte; Mylene Huebecker; Penelope J Hallett; Ole Isacson; Frances M Platt
Journal:  Glycoconj J       Date:  2021-11-10       Impact factor: 2.916

Review 2.  Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.

Authors:  Daniel Ysselstein; Tiffany J Young; Maria Nguyen; Shalini Padmanabhan; Warren D Hirst; Nicolas Dzamko; Dimitri Krainc
Journal:  Mov Disord       Date:  2021-10-06       Impact factor: 9.698

Review 3.  Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery.

Authors:  Ali Esfandiary; David Isaac Finkelstein; Nicolas Hans Voelcker; David Rudd
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

Review 4.  Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.

Authors:  Nohela B Arévalo; Cristian M Lamaizon; Viviana A Cavieres; Patricia V Burgos; Alejandra R Álvarez; María J Yañez; Silvana Zanlungo
Journal:  Front Mol Neurosci       Date:  2022-08-03       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.